clinical trials

News

Nicox plans filings for glaucoma after phase 3 win

Nicox is on track to file for approval of its therapy for eyesight-robbing disease glaucoma in the US and China after a second positive phase 3 trial.

News

Viking felled by dropout rates in oral obesity drug trial

Viking Therapeutics shares slumped on discontinuation rates with its oral obesity drug in a phase 2 trial, but are investors missing the point?

News

Pfizer suffers another hit to its GBT sickle cell portfolio

Pfizer's $5.4 billion takeover of Global Blood Therapeutics three years ago is starting to look like a poor deal.

News

Vedanta's microbiome therapy for IBD disappoints

Vedanta's microbiome therapy for ulcerative colitis has failed a phase 2 trial and will be shelved, prompting a 20% cut in workforce.

News

More good news in Sjogren's as RemeGen trial delivers

A second new drug, RemeGen's telitacicept, has shown efficacy in a phase 3 Sjögren's syndrome trial in the space of a week.

News

Padcev/Keytruda extends survival in early bladder cancer

Astellas and Pfizer plan to file Padcev for earlier-stage bladder cancer after showing a survival benefit in a combination regimen with Keytruda.

Nicox plans filings for glaucoma after phase 3 win

Viking felled by dropout rates in oral obesity drug trial

Pfizer suffers another hit to its GBT sickle cell portfolio

Vedanta's microbiome therapy for IBD disappoints

More good news in Sjogren's as RemeGen trial delivers

Padcev/Keytruda extends survival in early bladder cancer

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

clinical trials

Editor's Picks